Crossmark

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Crossref DOI link: https://doi.org/10.1186/s12969-019-0358-x

Published Online: 2019-09-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khraishi, Majed

Millson, Brad

Woolcott, John

Jones, Heather

Marshall, Lisa

Ruperto, Nicolino https://orcid.org/0000-0001-8407-7782
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2019-09-10

Version of Record valid from 2019-09-10
More Information

Article History

Received: 13 February 2019

Accepted: 7 August 2019

First Online: 10 September 2019

Ethics approval and consent to participate

: N/A

: N/A

: MK is an advisor for Pfizer and Amgen.BM is an employee of IQVIA and was contracted by Pfizer in connection with the development of this manuscript.JW is an employee of Pfizer.HJ was an employee of Pfizer when this study was conducted.LM was an employee of Pfizer when this study was conducted.NR has received honoraria for consultancies or speaker bureaus (< 10.000 USD each) from the following pharmaceutical companies in the past 3 years: Ablynx, AbbVie, Astrazeneca-Medimmune, Biogen, Boehringer, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Hoffmann-La Roche, Janssen, Merck, Novartis, Pfizer, R-Pharma, SanofiServier, Sinergie, Sobi and Takeda.The Gaslini Hospital, where NR works as full-time public employee, has received contributions (> 10.000 USD each) from the following industries in the last 3 years: BMS, Eli-Lilly, GlaxoSmithKline, F Hoffmann-La Roche, Janssen, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties.

Document is current

Any future updates will be listed below